Filing Flows › Organon (OGN) › Q3 2026 › vs Q3 2025
Organon (OGN) Q3 2026 vs Q3 2025 (year over year)
Organon's revenue fell $28.0M (-2%) from $1.6B in Q3 2025 to $1.6B in Q3 2026. Gross margin 55.2% against 53.5% (+1.7 pts).
Organon, Q3 2026: revenue $1.6B (-2% year over year), operating margin 16.2%, net earnings $164M, operating cash flow $370M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 55.2% | 53.5% | +1.7 pts |
| Operating margin | 16.2% | 15.2% | +1.0 pts |
| Net margin | 10.4% | 10.0% | +0.4 pts |
| Free cash flow margin | 20.7% | 13.6% | +7.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.6B | $1.6B | −$28.0M | -2% |
| Gross profit | $869M | $857M | $12.0M | +1% |
| Cost of revenue | $705M | $745M | −$40.0M | -5% |
| Operating profit | $255M | $243M | $12.0M | +5% |
| Operating expenses | $614M | $614M | $0 | 0% |
| Pre-tax earnings | $255M | $243M | $12.0M | +5% |
| Research & development | $83.0M | $84.0M | −$1.0M | -1% |
| SG&A | $421M | $415M | $6.0M | +1% |
| Other operating costs | $110M | $115M | −$5.0M | -4% |
| Net earnings | $164M | $160M | $4.0M | +2% |
| Income tax | $91.0M | $83.0M | $8.0M | +10% |
| Depreciation | $34.0M | $40.0M | −$6.0M | -15% |
| Share-based compensation | $21.0M | $24.0M | −$3.0M | -12% |
| Working capital & other | $151M | $40.0M | $111M | +278% |
| Operating cash flow | $370M | $264M | $106M | +40% |
| Free cash flow (OCF − capex) | $326M | $218M | $108M | +50% |
| Capital expenditures | $44.0M | $46.0M | −$2.0M | -4% |
Questions
How much did Organon's revenue grow year over year in Q3 2026?
Organon's revenue fell $28.0M (-2%) from $1.6B in Q3 2025 to $1.6B in Q3 2026. Gross margin 55.2% against 53.5% (+1.7 pts).